| UCB-Pharma SA - Xyzal, comprimés pelliculés |
| 55754 | | 01 | | Xyzal | | comprimés pelliculés | | R06AE09 | | Levocetirizine | | 26.09.2001 | | |
|
| Composition |
| levocetirizini dihydrochloridum 5 mg, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 63.5 mg, magnesii stearas, pellicule: hypromellosum, macrogolum 400, E 171, pro compresso obducto. |
| Packungsbestandteile |
| Coated tablets | | | | | Active Agent | Dose |
|---|
| Levocetirizine Dihydrochloride | 5 mg |
| | BAG: Active Agent | Dose |
|---|
| Levocetirizine Dihydrochloride | 5 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Cellulosum Microcristallinum | | | | E 171 | | color. | | Hypromellosum | | pellicule | | Lactose Monohydrate | 63.5 mg | | | Macrogol | 400 | | | Magnesii Stearas | | | | Pro Compresso Obducto | | | | Silica Colloidalis Anhydrica | | |
| |
|
| Teilbarkeit |
| | Ja | | | | schwierig | | | | Ja | | | | -- | | | | Tabletten sind schwierig zu suspendieren, Sonde kann verstopfen; Abends einnehmen | | | | | |
|
|
